CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 32,065 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
CSL Ltd hisse başına yıllık % {var1} temettüye sahiptir ve % {var2} oranında bir getiri sunmaktadır. Temettü altı ayda bir ödenmektedir ve son temettü hariç tarihi Sep 9, 2025 tarihindedir.
Dividend Yield
Yıllık Dividende
Özsermaye Tarihi
0.00%
$2.85
Sep 9, 2025
Ödeme Sıklığı
Ödeme Oranı
Altı ayda bir
0.00%
Dividend History
Özsermaye Tarihi
Nakit Tutarı
Kayıt Tarihi
Ödeme Tarihi
Sep 9, 2025
$2.4508
Sep 10, 2025
Oct 3, 2025
Mar 10, 2025
$2.0711
Mar 11, 2025
Apr 9, 2025
Sep 9, 2024
$2.1746
Sep 10, 2024
Oct 2, 2024
Mar 11, 2024
$1.7989
Mar 12, 2024
Apr 3, 2024
Sep 11, 2023
$2.0938
Sep 12, 2023
Oct 4, 2023
Mar 9, 2023
$1.6215
Mar 10, 2023
Apr 5, 2023
Dividend Grafikleri
CMXHF Kâr Payları
CMXHF Dividend Growth (Yıllık Üstünlük)
Follow-Up Questions
CSL Ltd'in şu anki temettü ödemesi ve yıllık temettüsü nedir?